JP2024545741A - 単一特異性および二重特異性抗体ならびにその抗原結合断片 - Google Patents

単一特異性および二重特異性抗体ならびにその抗原結合断片 Download PDF

Info

Publication number
JP2024545741A
JP2024545741A JP2024513739A JP2024513739A JP2024545741A JP 2024545741 A JP2024545741 A JP 2024545741A JP 2024513739 A JP2024513739 A JP 2024513739A JP 2024513739 A JP2024513739 A JP 2024513739A JP 2024545741 A JP2024545741 A JP 2024545741A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
heavy chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545741A5 (enExample
Inventor
バンサル，レカ
Original Assignee
ノーベルメッド セラピューティクス インコーポレイテッド．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノーベルメッド セラピューティクス インコーポレイテッド． filed Critical ノーベルメッド セラピューティクス インコーポレイテッド．
Publication of JP2024545741A publication Critical patent/JP2024545741A/ja
Publication of JP2024545741A5 publication Critical patent/JP2024545741A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024513739A 2021-08-31 2022-08-31 単一特異性および二重特異性抗体ならびにその抗原結合断片 Pending JP2024545741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/462,795 US11981727B2 (en) 2021-08-31 2021-08-31 Monospecific and bispecific antibodies and antigen binding fragments thereof
US17/462,795 2021-08-31
PCT/US2022/075723 WO2023034842A2 (en) 2021-08-31 2022-08-31 Monospecific and bispecific antibodies and antigen binding fragments thereof

Publications (2)

Publication Number Publication Date
JP2024545741A true JP2024545741A (ja) 2024-12-11
JP2024545741A5 JP2024545741A5 (enExample) 2025-09-02

Family

ID=85386669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513739A Pending JP2024545741A (ja) 2021-08-31 2022-08-31 単一特異性および二重特異性抗体ならびにその抗原結合断片

Country Status (7)

Country Link
US (2) US11981727B2 (enExample)
EP (1) EP4396226A4 (enExample)
JP (1) JP2024545741A (enExample)
CN (1) CN118475605A (enExample)
AU (1) AU2022337266A1 (enExample)
CA (1) CA3230258A1 (enExample)
WO (1) WO2023034842A2 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112850A2 (en) * 2010-03-10 2011-09-15 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
JP2020505075A (ja) * 2017-01-27 2020-02-20 ウルトラヒューマン ワン リミティド 結合剤
JP2021515542A (ja) * 2018-03-08 2021-06-24 ウルトラヒューマン エイト リミテッド Ｐｄ１結合剤
JP2021519100A (ja) * 2018-03-27 2021-08-10 ウルトラヒューマン トゥー リミテッド Ｃｄ４７結合剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756490B2 (en) 1997-08-26 2003-01-16 Abgenix, Inc. A process for inhibiting complement activation via the alternative pathway
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
US9745367B2 (en) 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
CA2685208C (en) 2007-04-24 2014-04-08 Novelmed Therapeutics, Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
DK2262831T3 (en) 2008-03-03 2015-04-27 Novelmed Therapeutics Inc ANTI-Properdin ANTIBODIES
US20140127204A1 (en) 2010-09-03 2014-05-08 Novelmed Therapeutics, Inc. Anti-properdin antibodies
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
EP2544694B1 (en) * 2010-03-02 2018-10-31 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin
WO2013102123A2 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
US9243070B2 (en) 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
AU2013243574B2 (en) 2012-04-03 2017-12-07 Novelmed Therapeutics, Inc Humanized and chimeric anti-factor C3 antibodies and uses thereof
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
EP3086809A4 (en) 2013-12-24 2017-11-29 NovelMed Therapeutics, Inc. Compositions and methods of treating ocular diseases
KR20260069620A (ko) 2017-01-30 2026-05-15 알렉시온 파마슈티칼스, 인코포레이티드 1가 항-프로페르딘 항체 및 항체 단편

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112850A2 (en) * 2010-03-10 2011-09-15 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
JP2020505075A (ja) * 2017-01-27 2020-02-20 ウルトラヒューマン ワン リミティド 結合剤
JP2021515542A (ja) * 2018-03-08 2021-06-24 ウルトラヒューマン エイト リミテッド Ｐｄ１結合剤
JP2021519100A (ja) * 2018-03-27 2021-08-10 ウルトラヒューマン トゥー リミテッド Ｃｄ４７結合剤

Also Published As

Publication number Publication date
US11981727B2 (en) 2024-05-14
US20230073274A1 (en) 2023-03-09
CA3230258A1 (en) 2023-03-09
US20250042981A1 (en) 2025-02-06
AU2022337266A1 (en) 2024-03-14
EP4396226A2 (en) 2024-07-10
CN118475605A (zh) 2024-08-09
WO2023034842A2 (en) 2023-03-09
EP4396226A4 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
JP7811315B2 (ja) 補体関連疾患のための融合タンパク質構築物
US12497445B2 (en) Monovalent anti-properdin antibodies and antibody fragments
CN104220454B (zh) 人源化的嵌合抗因子Bb抗体及其用途
JP7684803B2 (ja) 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP2024518724A (ja) 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途
CN106062193B (zh) 与人tlr2及人tlr4结合的双特异性抗体
EP4396226A2 (en) Monospecific and bispecific antibodies and antigen binding fragments thereof
WO2024108529A1 (en) Properdin binding protein and use thereof
CA3123004C (en) Fusion protein constructs for complement associated disease
RU2824402C2 (ru) Конструкции слитого белка для заболевания, связанного с комплементом

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260519